Search Page
Save citations to file
Email citations
Send citations to clipboard
Add to Collections
Add to My Bibliography
Create a file for external citation management software
Your saved search
Your RSS Feed
Filters
Results by year
Table representation of search results timeline featuring number of search results per year.
Year | Number of Results |
---|---|
2013 | 1 |
2014 | 1 |
2018 | 1 |
2024 | 0 |
Search Results
3 results
Results by year
Filters applied: . Clear all
It looks like you are searching for an author.
Results are currently sorted by Best Match. To see the newest results first,
change the sort order to Most Recent.
Page 1
Comparison of empagliflozin and glimepiride as add-on to metformin in patients with type 2 diabetes: a 104-week randomised, active-controlled, double-blind, phase 3 trial.
Lancet Diabetes Endocrinol. 2014 Sep;2(9):691-700. doi: 10.1016/S2213-8587(14)70120-2. Epub 2014 Jun 16.
Lancet Diabetes Endocrinol. 2014.
PMID: 24948511
Clinical Trial.
Empagliflozin compared with glimepiride in metformin-treated patients with type 2 diabetes: 208-week data from a masked randomized controlled trial.
Ridderstråle M, Rosenstock J, Andersen KR, Woerle HJ, Salsali A; EMPA-REG H2H-SU trial investigators.
Ridderstråle M, et al.
Diabetes Obes Metab. 2018 Dec;20(12):2768-2777. doi: 10.1111/dom.13457. Epub 2018 Aug 7.
Diabetes Obes Metab. 2018.
PMID: 29961998
Clinical Trial.
Item in Clipboard
Rationale, design and baseline characteristics of a 4-year (208-week) phase III trial of empagliflozin, an SGLT2 inhibitor, versus glimepiride as add-on to metformin in patients with type 2 diabetes mellitus with insufficient glycemic control.
Ridderstråle M, Svaerd R, Zeller C, Kim G, Woerle HJ, Broedl UC; EMPA-REG H2H-SU trial investigators.
Ridderstråle M, et al.
Cardiovasc Diabetol. 2013 Sep 5;12:129. doi: 10.1186/1475-2840-12-129.
Cardiovasc Diabetol. 2013.
PMID: 24007456
Free PMC article.
Clinical Trial.
Item in Clipboard
Cite
Cite